DK4009978T3 - Anvendelse af Sepiapterin og metabolitter deraf for at behandle strålingseksponering - Google Patents

Anvendelse af Sepiapterin og metabolitter deraf for at behandle strålingseksponering Download PDF

Info

Publication number
DK4009978T3
DK4009978T3 DK20758407.9T DK20758407T DK4009978T3 DK 4009978 T3 DK4009978 T3 DK 4009978T3 DK 20758407 T DK20758407 T DK 20758407T DK 4009978 T3 DK4009978 T3 DK 4009978T3
Authority
DK
Denmark
Prior art keywords
sepiapterin
metabolites
radiation exposure
treat radiation
treat
Prior art date
Application number
DK20758407.9T
Other languages
Danish (da)
English (en)
Inventor
Eleonora Mezzaroma
Christopher Rabender
Ross Mikkelsen
Vasily Yakovlev
Neil Smith
Original Assignee
Ptc Therapeutics Mp Inc
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc, Univ Virginia Commonwealth filed Critical Ptc Therapeutics Mp Inc
Application granted granted Critical
Publication of DK4009978T3 publication Critical patent/DK4009978T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DK20758407.9T 2019-08-05 2020-08-05 Anvendelse af Sepiapterin og metabolitter deraf for at behandle strålingseksponering DK4009978T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Publications (1)

Publication Number Publication Date
DK4009978T3 true DK4009978T3 (da) 2024-10-14

Family

ID=72148243

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20758407.9T DK4009978T3 (da) 2019-08-05 2020-08-05 Anvendelse af Sepiapterin og metabolitter deraf for at behandle strålingseksponering

Country Status (21)

Country Link
US (1) US12667569B2 (cg-RX-API-DMAC10.html)
EP (2) EP4454712A3 (cg-RX-API-DMAC10.html)
JP (2) JP7642611B2 (cg-RX-API-DMAC10.html)
CN (2) CN119837879A (cg-RX-API-DMAC10.html)
AU (1) AU2020324435B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022002029A2 (cg-RX-API-DMAC10.html)
CA (1) CA3146477A1 (cg-RX-API-DMAC10.html)
DK (1) DK4009978T3 (cg-RX-API-DMAC10.html)
ES (1) ES2994060T3 (cg-RX-API-DMAC10.html)
FI (1) FI4009978T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20241653T1 (cg-RX-API-DMAC10.html)
HU (1) HUE069012T2 (cg-RX-API-DMAC10.html)
IL (1) IL290321B2 (cg-RX-API-DMAC10.html)
LT (1) LT4009978T (cg-RX-API-DMAC10.html)
MX (1) MX2022001535A (cg-RX-API-DMAC10.html)
PL (1) PL4009978T3 (cg-RX-API-DMAC10.html)
PT (1) PT4009978T (cg-RX-API-DMAC10.html)
RS (1) RS66096B1 (cg-RX-API-DMAC10.html)
SI (1) SI4009978T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202500089T1 (cg-RX-API-DMAC10.html)
WO (1) WO2021026247A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
WO2005048926A2 (en) * 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
CA2545968C (en) 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
CN101132776A (zh) 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
KR20160065998A (ko) 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
JP5066756B2 (ja) 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
JP6084967B2 (ja) 2012-05-07 2017-02-22 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
JP2016530333A (ja) * 2013-09-13 2016-09-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 放射線の影響から防護するため及び放射線の影響を緩和するための組成物の調製及び使用
CN114306208A (zh) * 2014-10-02 2022-04-12 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗的用途
WO2018019931A1 (en) 2016-07-29 2018-02-01 Dipharma S.A. Pharmaceutical composition kit comprising sapropterin dihydrochloride
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) * 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
CA3165636A1 (en) 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
IL305037A (en) 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
AR127191A1 (es) 2021-09-29 2023-12-27 Ptc Therapeutics Inc Composición farmacéutica de sepiapterina

Also Published As

Publication number Publication date
EP4009978A1 (en) 2022-06-15
EP4454712A2 (en) 2024-10-30
SMT202500089T1 (it) 2025-03-12
ES2994060T3 (en) 2025-01-16
CA3146477A1 (en) 2021-02-11
IL290321B2 (en) 2026-08-01
US12667569B2 (en) 2026-06-30
US20220273661A1 (en) 2022-09-01
EP4454712A3 (en) 2025-01-01
CN114555090A (zh) 2022-05-27
IL290321A (en) 2022-04-01
PT4009978T (pt) 2024-11-05
HRP20241653T1 (hr) 2025-04-25
PL4009978T3 (pl) 2025-02-24
JP7642611B2 (ja) 2025-03-10
AU2020324435B2 (en) 2026-03-19
LT4009978T (lt) 2024-11-25
RS66096B1 (sr) 2024-11-29
JP2022543655A (ja) 2022-10-13
BR112022002029A2 (pt) 2022-06-07
FI4009978T3 (fi) 2024-11-01
IL290321B1 (en) 2026-04-01
CN119837879A (zh) 2025-04-18
EP4009978B1 (en) 2024-09-25
MX2022001535A (es) 2022-03-04
AU2020324435A1 (en) 2022-02-24
HUE069012T2 (hu) 2025-02-28
CN114555090B (zh) 2024-12-17
SI4009978T1 (sl) 2025-03-31
WO2021026247A1 (en) 2021-02-11
JP2025098011A (ja) 2025-07-01

Similar Documents

Publication Publication Date Title
IL290321A (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
DK4045039T3 (da) Hæmning af human integrin-alfa4beta7
DK3810581T3 (da) Krystalmodifikationer af odevixibat
DK3784663T3 (da) Substituerede 4-aminoisoindolin-1,3-dionforbindelser og deres anvendelse til behandlng af et lymfom
IL280258A (en) Methods of using a gip/glp1 co-agonist for therapy
DK3455259T5 (da) Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling
DK3880660T3 (da) Forbindelser og sammensætninger til behandling af tilstande forbundet med nlrp-aktivitet
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3877052T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3554631T3 (da) Behandling af patienter med ttfields med elektrodepositionerne optimeret under anvendelse af deformerbare skabeloner
DK4331584T3 (da) Terapeutiske anvendelser af deutererede derivater af lanifibranor
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
DK4434585T3 (da) Forbindelser og fremgangsmåder til reduktion af snca-ekspression
DK3806898T3 (da) Gremlin-1-antagonist til anvendelse i behandling af cancer
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
DK3801534T3 (da) Behandling af fenylketonuri med sepiapterin
DK3574135T3 (da) Fremgangsmåde og formulering til fremstilling af ligninfibre
IL290231A (en) Mhc class ii molecules and methods of use thereof
IL290223A (en) Mhc class ii molecules and methods of use thereof
DK4419526T3 (da) Heterocykliske forbindelser til anvendelse i behandlingen af cancer
EP3692973A4 (en) BACK SUPPORT FOR ANKLE SPHAT, AND ANKLE SPHAT
DK3864053T3 (da) Behandling af rms ved at skifte terapi
DK3897455T3 (da) Medicinsk fastgørelsesindretning til fastgørelse af transplantaert
DK3927899T3 (da) Nedvibrering af funderinger